Development of a nonreplicative phage-based DNA delivery system and its application to antimicrobial therapies

Phage therapy has emerged as a promising alternative to conventional antimicrobial therapy for antimicrobial-resistant bacterial infections, but concerns about uncontrolled phage proliferation have limited its use. To address this issue, we established a nonproliferative phage-based DNA delivery system, called bacteria-targeting capsid particle (B-CAP), for the development of antimicrobial agents which effectively prevented phage spread while maintaining bactericidal activity. B-CAP is principally a T7 phage capsids packaged with a partial T7 phage genome, giving it the allowance to accommodate large foreign DNA up to 18 kb in length. We confirmed the efficacy of B-CAP in targeting and injecting its genome into bacteria, analogous to the wild-type phage. To demonstrate proof-of-concept and potential for developing an antimicrobial agent, we loaded colicin E1 operon onto the B-CAP system, resulting in the construction of B-CAP_ColE1, an antimicrobial agent capable of boosting colicin E1-based bacterial killing against Escherichia <i>coli</i>. Although no therapeutic effect was observed for B-CAP, B-CAP_ColE1 exhibited strong bactericidal activity against carbapenem-resistant <i>E. coli</i> both in vitro and in vivo, and significantly improved the survival of mice in an infection mouse model experiment. Finally, B-CAP_ColE1 is biologically contained or inert, reducing potential biological hazards during therapeutic use. Our results demonstrate that the B-CAP system offers a new strategy for developing nonreplicative phage-based antimicrobial agents against bacterial infections.